← All trials
NCT04385342
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2020
- Primary completion
- May 30, 2022
- Completion date
- Aug 31, 2022
- First posted
- May 12, 2020
- Last posted
- May 13, 2020
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mansoura UniversityLead sponsor
- Alexandria UniversityStudy director
- Mansoura UniversityStudy chair
- Mansoura UniversityStudy director
- Mansoura UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.